Novartis Ag (NVS) Change in Account Payables (2022 - 2025)

Novartis Ag (NVS) has 4 years of Change in Account Payables data on file, last reported at -$172.0 million in Q1 2025.

• Quarterly Change in Account Payables rose 57.95% year-over-year to -$172.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$637.0 million (changed N/A YoY) and the FY2017 annual result came in at $58.0 million, changed N/A from the prior year.
• Change in Account Payables advanced to -$172.0 million in Q1 2025 per NVS's latest filing, from -$409.0 million in the prior quarter.
• The five-year high for Change in Account Payables was $87.0 million in Q1 2023, with the low at -$409.0 million in Q1 2024.
• Average Change in Account Payables over 4 years is -$159.2 million, with a median of -$157.5 million recorded in 2022.
• Year-over-year, Change in Account Payables surged 160.84% in 2023 and tumbled 570.11% in 2024.
• Novartis Ag's Change in Account Payables stood at -$143.0 million in 2022, then surged by 160.84% to $87.0 million in 2023, then plunged by 570.11% to -$409.0 million in 2024, then soared by 57.95% to -$172.0 million in 2025.
• Business Quant data shows NVS's Change in Account Payables at -$172.0 million in Q1 2025, -$409.0 million in Q1 2024, and $87.0 million in Q1 2023.